Bill Ackman is getting slammed in 2016
Thomson ReutersWilliam Ackman, founder and CEO of hedge fund Pershing Square Capital Management, speaks during the Sohn Investment Conference in New York
Current Prices
Sponsored by
| Symbol | Price | Change | %Change | |
|---|---|---|---|---|
| APD | 117.90 | +0.30 | +0.30 | |
| CP | 100.30 | -3.89 | -3.70 | |
| HHC | 96.84 | +1.69 | +1.80 | |
| HLF | 46.25 | +0.07 | +0.20 | |
| MDLZ | 40.40 | -0.27 | -0.70 | |
| PAH | 7.59 | -0.08 | -1.00 | |
| QSR | 33.91 | +1.28 | +3.90 | |
| VRX | 90.49 | +1.07 | +1.20 | |
| ZTS | 43.45 | -0.35 | -0.80 |
Hedge fund titan Bill Ackman's Pershing Square Holdings, the fund's publicly traded vehicle, has fallen 14.5% in 2016, according to a performance update.
That performance is through January 19.
Pershing Square had its worst year in its history last year, falling 20.5%.
Ackman, a well-known activist investor, makes large, concentrated bets in a handful companies.
His five largest holdings include Valeant Pharmaceutical (-12% year-to-date), Air Products & Chemicals (-9.6%), Canadian Pacific (-18%), Mondelez (-9.3%), and Zoetis (-8.6%).
Ackman is also an investor in Platform Speciality Products, which has dropped 40% this year. Meanwhile, Howard Hughes Corp, another one of his long equity holdings, has fallen about 15%.
Ackman's only short is Herbalife, a multi-level marketing company that sells weight loss shakes. Ackman has been crusading against Herbalife since December 2012 because he believes the company is a "pyramid scheme." He's betting that the stock goes to $0.
Shares of Herbalife have fallen more than 13% this year.
No comments:
Post a Comment